167 related articles for article (PubMed ID: 22876949)
21. Review in quantitative structure activity relationships on lipoxygenase inhibitors.
Eleni P; Dimitra HL
Mini Rev Med Chem; 2003 Aug; 3(5):487-99. PubMed ID: 12769699
[TBL] [Abstract][Full Text] [Related]
22. Anticancer Activity of Natural and Synthetic Chalcones.
Constantinescu T; Lungu CN
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768736
[TBL] [Abstract][Full Text] [Related]
23. In vitro anti-proliferative effect of naturally occurring oxyprenylated chalcones.
Fiorito S; Epifano F; Bruyère C; Kiss R; Genovese S
Nat Prod Commun; 2013 Aug; 8(8):1089-92. PubMed ID: 24079174
[TBL] [Abstract][Full Text] [Related]
24. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
25. Cytokines in terms of QSAR. Review, evaluation and comparative studies.
Konstantinidou M; Hadjipavlou-Litina D
SAR QSAR Environ Res; 2013 Nov; 24(11):883-962. PubMed ID: 24099567
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of novel analogs of 2-pyrazoline obtained from [(7-chloroquinolin-4-yl)amino]chalcones and hydrazine as potential antitumor and antimalarial agents.
Insuasty B; Montoya A; Becerra D; Quiroga J; Abonia R; Robledo S; Vélez ID; Upegui Y; Nogueras M; Cobo J
Eur J Med Chem; 2013 Sep; 67():252-62. PubMed ID: 23871905
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.
Pontiki E; Hadjipavlou-Litina D
Med Res Rev; 2012 Jan; 32(1):1-165. PubMed ID: 20162725
[TBL] [Abstract][Full Text] [Related]
28. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?
Boumendjel A; Ronot X; Boutonnat J
Curr Drug Targets; 2009 Apr; 10(4):363-71. PubMed ID: 19355861
[TBL] [Abstract][Full Text] [Related]
29. A natural chalcone induces apoptosis in lung cancer cells: 3D-QSAR, docking and an in vivo/vitro assay.
Chen G; Zhou D; Li XZ; Jiang Z; Tan C; Wei XY; Ling J; Jing J; Liu F; Li N
Sci Rep; 2017 Sep; 7(1):10729. PubMed ID: 28878321
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells.
Dos Santos MB; Bertholin Anselmo D; de Oliveira JG; Jardim-Perassi BV; Alves Monteiro D; Silva G; Gomes E; Lucia Fachin A; Marins M; de Campos Zuccari DAP; Octavio Regasini L
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1093-1099. PubMed ID: 31117836
[TBL] [Abstract][Full Text] [Related]
31. Novel 3',5'-diprenylated chalcones inhibited the proliferation of cancer cells in vitro by inducing cell apoptosis and arresting cell cycle phase.
Wen Z; Zhang Y; Wang X; Zeng X; Hu Z; Liu Y; Xie Y; Liang G; Zhu J; Luo H; Xu B
Eur J Med Chem; 2017 Jun; 133():227-239. PubMed ID: 28390228
[TBL] [Abstract][Full Text] [Related]
32. A Review on Mechanisms of Anti Tumor Activity of Chalcones.
Sharma R; Kumar R; Kodwani R; Kapoor S; Khare A; Bansal R; Khurana S; Singh S; Thomas J; Roy B; Phartyal R; Saluja S; Kumar S
Anticancer Agents Med Chem; 2015; 16(2):200-11. PubMed ID: 25980813
[TBL] [Abstract][Full Text] [Related]
33. Niacin esters of chalcones with tumor-selective properties.
Panda AK; Das U; Roayapalley PK; Sakagami H; Kawase M; Balzarini J; De Clercq E; Dimmock JR
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1451-6. PubMed ID: 27251045
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones.
Yamali C; Gul HI; Ozgun DO; Sakagam H; Umemura N; Kazaz C; Gul M
Anticancer Agents Med Chem; 2017; 17(10):1426-1433. PubMed ID: 28356013
[TBL] [Abstract][Full Text] [Related]
35. The products of the reaction between 6-amine-1,3-dimethyl uracil and bis-chalcones induce cytotoxicity with massive vacuolation in HeLa cervical cancer cell line.
Solano JD; González-Sánchez I; Cerbón MA; Guzmán Á; Martínez-Urbina MA; Vilchis-Reyes MA; Martínez-Zuñiga EC; Alvarado C; Quintero A; Díaz E
Eur J Med Chem; 2013 Feb; 60():350-9. PubMed ID: 23314048
[TBL] [Abstract][Full Text] [Related]
36. Overcoming tumor drug resistance with C2-modified 10-deacetyl-7-propionyl cephalomannines: a QSAR study.
Hansch C; Verma RP
Mol Pharm; 2009; 6(3):849-60. PubMed ID: 19334723
[TBL] [Abstract][Full Text] [Related]
37. Heterocyclic chalcone analogues as potential anticancer agents.
Sharma V; Kumar V; Kumar P
Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Evaluation of (2-(Pyridinyl)methylene)-1-tetralone Chalcones for Anticancer and Antimicrobial Activity.
Gibson MZ; Nguyen MA; Zingales SK
Med Chem; 2018; 14(4):333-343. PubMed ID: 29065840
[TBL] [Abstract][Full Text] [Related]
39. Recent trends of chalcones potentialities as antiproliferative and antiresistance agents.
Winter E; Locatelli C; Di Pietro A; Creczynski-Pasa TB
Anticancer Agents Med Chem; 2015; 15(5):592-604. PubMed ID: 25553434
[TBL] [Abstract][Full Text] [Related]
40. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
